Identifying qualitative differences in PPARα signaling networks in human and rat hepatocytes and their significance for next generation chemical risk assessment methods.
暂无分享,去创建一个
Melvin E. Andersen | Rebecca A. Clewell | Patrick D. McMullen | Salil N. Pendse | Sudin Bhattacharya | Chad Deisenroth | M. Andersen | R. Clewell | C. Woods | S. Bhattacharya | P. McMullen | Edward L. LeCluyse | V. Soldatow | E. LeCluyse | C. Deisenroth | Courtney G. Woods | Mary T. McBride | Valerie Y. Soldatow | S. Pendse | M. McBride
[1] O. G. Fitzhugh,et al. 100-Fold margin of safety , 1954 .
[2] N. Lalwani,et al. Excessive accumulation of autofluorescent lipofuscin in the liver during hepatocarcinogenesis by methyl clofenapate and other hypolipidemic peroxisome proliferators. , 1982, Cancer research.
[3] K. Decker,et al. Synthesis of prostanoids and cyclic nucleotides by phagocytosing rat Kupffer cells. , 1984, European journal of biochemistry.
[4] A. Buckley,et al. Rapid activation of protein kinase C in isolated rat liver nuclei by prolactin, a known hepatic mitogen. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[5] T. Decker,et al. Comparative Study of Cytotoxicity, Tumor Necrosis Factor, and Prostaglandin Release After Stimulation of Rat Kupffer Cells, Murine Kupffer Cells, and Murine Inflammatory Liver Macrophages , 1989, Journal of leukocyte biology.
[6] R. Cattley,et al. Relationship of oxidative damage to the hepatocarcinogenicity of the peroxisome proliferators di(2-ethylhexyl)phthalate and Wy-14,643. , 1989, Carcinogenesis.
[7] K. Decker,et al. Biologically active products of stimulated liver macrophages (Kupffer cells). , 1990, European journal of biochemistry.
[8] J. Popp,et al. Dose-related effects of the hepatocarcinogen, Wy-14,643, on peroxisomes and cell replication. , 1992, Fundamental and applied toxicology : official journal of the Society of Toxicology.
[9] T. Goldsworthy,et al. Contrasting hepatocytic peroxisome proliferation, lipofuscin accumulation and cell turnover for the hepatocarcinogens Wy-14,643 and clofibric acid. , 1992, Carcinogenesis.
[10] H. Beyer,et al. Tumor necrosis factor-alpha is a direct hepatocyte mitogen in the rat. , 1993, Biochemistry and molecular biology international.
[11] G. Gil-Gómez,et al. Peroxisome proliferator-activated receptor mediates induction of the mitochondrial 3-hydroxy-3-methylglutaryl-CoA synthase gene by fatty acids. , 1994, The Journal of biological chemistry.
[12] D. Moore,et al. The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[13] J Auwerx,et al. Induction of the Acyl-Coenzyme A Synthetase Gene by Fibrates and Fatty Acids Is Mediated by a Peroxisome Proliferator Response Element in the C Promoter (*) , 1995, The Journal of Biological Chemistry.
[14] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[15] J. Hochman,et al. Cultured rat hepatocytes. , 1996, Pharmaceutical biotechnology.
[16] W. Wahli,et al. Polarity and Specific Sequence Requirements of Peroxisome Proliferator-activated Receptor (PPAR)/Retinoid X Receptor Heterodimer Binding to DNA , 1997, The Journal of Biological Chemistry.
[17] K. Griffin,et al. A Carboxyl-terminal Extension of the Zinc Finger Domain Contributes to the Specificity and Polarity of Peroxisome Proliferator-activated Receptor DNA Binding* , 1998, The Journal of Biological Chemistry.
[18] I. Rusyn,et al. Peroxisome proliferator-activated receptor alpha is restricted to hepatic parenchymal cells, not Kupffer cells: implications for the mechanism of action of peroxisome proliferators in hepatocarcinogenesis. , 2000, Carcinogenesis.
[19] R. Roberts,et al. Role of hepatic non-parenchymal cells in the response of rat hepatocytes to the peroxisome proliferator nafenopin in vitro. , 2000, Carcinogenesis.
[20] T. Willson,et al. Differential involvement of peroxisome-proliferator-activated receptors α and δ in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine , 2001 .
[21] W. Wilkison,et al. Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis. , 2001, Bioorganic & medicinal chemistry letters.
[22] R. Schulte‐Hermann,et al. Peroxisome proliferators do not increase DNA synthesis in purified rat hepatocytes. , 2001, Carcinogenesis.
[23] T. Yin,et al. Moderate iron overload enhances lipid peroxidation in livers of rats, but does not affect NF-kappaB activation induced by the peroxisome proliferator, Wy-14,643. , 2002, The Journal of nutrition.
[24] T. Speed,et al. Summaries of Affymetrix GeneChip probe level data. , 2003, Nucleic acids research.
[25] Gopal R. Gopinath,et al. Reactome: a knowledge base of biologic pathways and processes , 2007, Genome Biology.
[26] Atsushi Ono,et al. Profiling of gene expression in rat liver and rat primary cultured hepatocytes treated with peroxisome proliferators. , 2006, The Journal of toxicological sciences.
[27] J. Ibrahim,et al. Time course investigation of PPARalpha- and Kupffer cell-dependent effects of WY-14,643 in mouse liver using microarray gene expression. , 2007, Toxicology and applied pharmacology.
[28] Clifford A. Meyer,et al. Model-based Analysis of ChIP-Seq (MACS) , 2008, Genome Biology.
[29] S. Young,et al. The expression of GPIHBP1, an endothelial cell binding site for lipoprotein lipase and chylomicrons, is induced by peroxisome proliferator-activated receptor-gamma. , 2008, Molecular endocrinology.
[30] J. Corton,et al. Gene Profiling in the Livers of Wild-type and PPARα-Null Mice Exposed to Perfluorooctanoic Acid , 2008, Toxicologic pathology.
[31] Yoshitomo Hamuro,et al. Structure of the intact PPAR-γ–RXR-α nuclear receptor complex on DNA , 2008, Nature.
[32] J Christopher Corton,et al. Toxicogenomic dissection of the perfluorooctanoic acid transcript profile in mouse liver: evidence for the involvement of nuclear receptors PPAR alpha and CAR. , 2008, Toxicological sciences : an official journal of the Society of Toxicology.
[33] Michael Müller,et al. Comparative Analysis of Gene Regulation by the Transcription Factor PPARα between Mouse and Human , 2009, PloS one.
[34] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .
[35] P. D. de Groot,et al. Profiling of promoter occupancy by PPARα in human hepatoma cells via ChIP-chip analysis , 2010, Nucleic acids research.
[36] J. Bailar,et al. Toxicity Testing in the 21st Century: A Vision and a Strategy , 2010, Journal of toxicology and environmental health. Part B, Critical reviews.
[37] Melvin E. Andersen,et al. Toxicity Testing in the 21st Century: Defining New Risk Assessment Approaches Based on Perturbation of Intracellular Toxicity Pathways , 2011, PloS one.
[38] Philip Machanick,et al. MEME-ChIP: motif analysis of large DNA datasets , 2011, Bioinform..
[39] Melvin E. Andersen,et al. New directions in toxicity testing. , 2011, Annual review of public health.
[40] Michael D. Wilson,et al. A feedback loop between the liver-enriched transcription factor network and miR-122 controls hepatocyte differentiation. , 2012, Gastroenterology.
[41] Melvin E. Andersen,et al. Toxicogenomics for transcription factor-governed molecular pathways: moving on to roles beyond classification and prediction , 2012, Archives of Toxicology.
[42] J. Corton,et al. Mode of action framework analysis for receptor-mediated toxicity: The peroxisome proliferator-activated receptor alpha (PPARα) as a case study , 2014, Critical reviews in toxicology.
[43] Melvin E Andersen,et al. A map of the PPARα transcription regulatory network for primary human hepatocytes. , 2014, Chemico-biological interactions.
[44] Wen Xie,et al. Mode of action and human relevance analysis for nuclear receptor-mediated liver toxicity: A case study with phenobarbital as a model constitutive androstane receptor (CAR) activator , 2014, Critical reviews in toxicology.
[45] Melvin E. Andersen,et al. Incorporating High-Throughput Exposure Predictions With Dosimetry-Adjusted In Vitro Bioactivity to Inform Chemical Toxicity Testing , 2015, Toxicological sciences : an official journal of the Society of Toxicology.
[46] M. Andersen,et al. Development of an in vitro high content imaging assay for quantitative assessment of CAR-dependent mouse, rat, and human primary hepatocyte proliferation. , 2016, Toxicology in vitro : an international journal published in association with BIBRA.
[47] Melvin E Andersen,et al. Pathway Based Toxicology and Fit-for-Purpose Assays. , 2016, Advances in experimental medicine and biology.
[48] Michael B. Black,et al. Assessing molecular initiating events (MIEs), key events (KEs) and modulating factors (MFs) for styrene responses in mouse lungs using whole genome gene expression profiling following 1‐day and multi‐week exposures , 2017, Toxicology and applied pharmacology.
[49] Michael B. Black,et al. Strain‐related differences in mouse lung gene expression over a two‐year period of inhalation exposure to styrene: Relevance to human risk assessment , 2018, Regulatory toxicology and pharmacology : RTP.
[50] Harvey J Clewell,et al. Evaluating opportunities for advancing the use of alternative methods in risk assessment through the development of fit-for-purpose in vitro assays. , 2018, Toxicology in vitro : an international journal published in association with BIBRA.
[51] Michael B. Black,et al. Addressing systematic inconsistencies between in vitro and in vivo transcriptomic mode of action signatures. , 2019, Toxicology in vitro : an international journal published in association with BIBRA.